Kimberly Willis
Nurse Practitioner · Columbia, SCNPI 1558496448
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 393 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 6.9% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 393 payments — averaging $20.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$558
- Novartis$545
- Johnson & Johnson$543
- Merck$487
- Bristol Myers Squibb$451
- Lilly USA, LLC$418
- plus $5K from 54 others
What the payments were for
- Food & beverage$8,129100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$8,129 in reported general payments places this provider in the 95th percentile of 1,346 nurse practitioner providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 141 | $2,507,410 |
| BrukinsaZanubrutinib | 45 | $659,361 |
| ImbruvicaIbrutinib | 22 | $339,807 |
| CabometyxCabozantinib S-Malate | 13 | $314,310 |
| ErleadaApalutamide | 19 | $269,323 |
| VenclextaVenetoclax | 17 | $241,625 |
| Lenalidomide | 14 | $230,502 |
| Imatinib Mesylate | 69 | $58,056 |
| Abiraterone Acetate | 15 | $27,097 |
| EliquisApixaban | 32 | $24,700 |
| Letrozole | 72 | $1,504 |
| Hydroxyurea | 34 | $1,043 |
| Potassium Chloride | 55 | $942 |
| Dexamethasone | 39 | $545 |
| Anastrozole | 16 | $508 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $451 | $2,507,410141 claims |
| Beigene USA, Inc.Brukinsa | $79 | $659,36145 claims |
| Exelixis Inc.Cabometyx | $119 | $314,31013 claims |
| Johnson & JohnsonErleada | $543 | $269,32319 claims |
| AbbVieVenclexta | $106 | $241,62517 claims |
| PfizerEliquis | $558 | $24,70032 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,346 nurse practitioner providers in South Carolina.
Other nurse practitioner in Columbia
- Melissa BramanteColumbia$19K
- Tonya MeltonColumbia$11K
- Andrea OatesColumbia$9K
- Meredith WatsonColumbia$9K
- Leigh DavisColumbia$7K
- David WiltGreenville$90K
- Whitney ReedCharleston$54K
- Mary JohnsonCharleston$34K
- Amanda HareCharleston$30K
- Kellie McLainCharleston$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.